A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination with AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma

Patients with colon cancer who have been treated with one prior therapy for metastatic disease will be randomized to receive FOLFIRI with AMG 479 or AMG 655.